Abstract
Chronic liver diseases (CLDs) that lead to hepatic fibrosis, cirrhosis, and/or hepatocellular carcinoma (HCC) have become a major cause of illness and death worldwide. The main causative factors for CLDs are chronic viral infections, excessive alcohol consumption, non-alcoholic fatty liver disease (NAFLD), and cholestatic diseases. The primary approach to managing cirrhosis should be removing the causative agent, and the secondary approach should address fibrogenesis. Liver cancer is also a leading cause of death worldwide, and many therapeutic approaches exist to treat the disease. However, liver transplantation remains the last treatment option for cirrhosis and liver cancer. Thus, this review discusses the pathophysiology of liver fibrosis, its progression to cirrhosis and HCC, and current therapeutic options available to treat the diseases with potential therapeutic options that will be available in the near future.
Reference114 articles.
1. Rajapaksha, I., Gunarathne, L., Angus, P., and Herath, C. (2021). Update on New Aspects of the Renin-Angiotensin System in Hepatic Fibrosis and Portal Hypertension: Implications for Novel Therapeutic Options. J. Clin. Med., 10.
2. Genetic Diseases That Predispose to Early Liver Cirrhosis;Int. J. Hepatol.,2014
3. Extracellular matrix: Preconditioning the ECM for fibrosis;Nat. Rev. Mol. Cell Biol.,2014
4. Extracellular matrix and cell signalling: The dynamic cooperation of integrin, proteoglycan and growth factor receptor;J. Endocrinol.,2011
5. HEPATIC FIBROSIS: Pathogenesis and Principles of Therapy;Clin. Liver Dis.,2001
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献